Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCLBKK:HL 72 Return-on-Tangible-Equity is 7.94% as of Mar. 2026, which is 41% below its 10-year median of 13.43. GuruFocus rates BKK:HL with a GF Score™ of 72/100 and a GF Value™ of ฿10.90 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 576 Healthcare Providers & Services companies, Healthlead PCL ranks worse than 55.73% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Healthlead PCL's annualized net income for the quarter that ended in Mar. 2026 was ฿74 Mil. Healthlead PCL's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ฿934 Mil. Therefore, Healthlead PCL's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 7.94%.
The historical rank and industry rank for Healthlead PCL's Return-on-Tangible-Equity or its related term are showing as below:
BKK:HL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.98 Med: 13.43 Max: 47.6
Current: 7.98
During the past 7 years, Healthlead PCL's highest Return-on-Tangible-Equity was 47.60%. The lowest was 7.98%. And the median was 13.43%.
BKK:HL's Return-on-Tangible-Equity is ranked worse than 55.73% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.17
vs BKK:HL: 7.98
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Healthlead PCL Return-on-Tangible-Equity Related Terms
Healthlead PCL Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Healthlead PCL's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Healthlead PCL's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 7.94% mean?
Healthlead PCL (BKK:HL) has a Return-on-Tangible-Equity of 7.94% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Healthlead PCL and its competitors. This is 41% below median its historical median of 13.43. Over the past decade, Healthlead PCL's Return-on-Tangible-Equity has ranged from 7.98 to 47.60. According to the industry distribution chart, Healthlead PCL ranks #321 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 55.7%.
Is Healthlead PCL's Return-on-Tangible-Equity too high?
Healthlead PCL's current Return-on-Tangible-Equity of 7.94% is 41% below median its 10-year median of 13.43. Over the past 10 years, this metric has ranged from a low of 7.98 to a high of 47.60. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.17. Healthlead PCL's value of 7.94% is 21.9% below this industry median. Based on the distribution chart, Healthlead PCL ranks #321 out of 576 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Healthlead PCL has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #321 out of 576 companies for Return-on-Tangible-Equity. This places Healthlead PCL in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.17. Healthlead PCL's value of 7.94% is 21.9% below this benchmark. Historically, Healthlead PCL's own Return-on-Tangible-Equity has ranged from 7.98 to 47.60 over the past decade. While the company's 10-year median is 13.43 vs. the industry median of 10.17, Healthlead PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthlead PCL's current Return-on-Tangible-Equity of 7.94% is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Healthlead PCL and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current Return-on-Tangible-Equity is 7.94%, which is 41% below median its own 10-year median of 13.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.90, compared to a current price of ฿5.85 — trading 46.3% below its estimated fair value. The current Return-on-Tangible-Equity is 7.94%, which is 41% below median its 10-year median of 13.43 and 21.9% below the Healthcare Providers & Services industry median of 10.17. Healthlead PCL's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current Return-on-Tangible-Equity is 7.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿5.85 is trading 46.3% below its estimated GF Value™ of ฿10.90.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
Return-on-Tangible-Equity: 7.94% (41% below median its 10-year median of 13.43)
GF Value™: ฿10.90 vs. price of ฿5.85 (46.3% below fair value)
Industry Position: 21.9% below the Healthcare Providers & Services median (#321 of 576)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
72GF Score
Get the complete analysis for BKK:HL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
